Best Practices for pharma commercialization in market access

Pharmaceutical market access, sales, and field teams rely on high-quality, effective content to demonstrate their products’ value globally. As companies expand internationally, effectively rolling out content that meets global and local needs becomes challenging. These materials typically include

• value dossiers, which present comprehensive evidence of a product’s clinical and economic value
• budget impact models that help stakeholders evaluate the financial implications of adopting a product
• health economics and outcomes research (HEOR) tools
• promotional materials and educational resources tailored to specific audiences

These diverse content types are vital in supporting your pharma commercialization strategy. Collectively, they inform reimbursement discussions and drive sales initiatives in the complex and competitive pharmaceutical landscape.

The need for localized evidence, varying product approval timelines, and regional regulatory requirements often complicate the process. Additionally, ensuring content is easily and accurately translated is essential to reaching audiences in different languages and regions. This blog will explore the challenges in international content roll-out. We’ll also share best practices to help pharma teams navigate these complexities.

• Regional teams are often concerned that materials created by global teams lack local relevance. Global teams may not incorporate country-specific data, regulatory requirements, or market nuances in their content. Materials that miss this localized focus may not resonate with healthcare providers, payers, and other key stakeholders.
• Local market needs often include:
  • evidence that aligns with regional health economic data,
  • local case studies, or
  • culturally relevant messaging.

When you don’t localize content in pharma, even well-designed materials may struggle to have impact.

• Pharma products often receive staggered approvals across different countries. This creates unique challenges in content management. For example, one country may approve a product for a specific indication. However, a product may still be awaiting approval for the same or a different indication in another country.
• Such variations mean that materials must adapt to each product’s precise regulatory and approval status in each market. Content must be flexible so regional teams can adjust it without compromising its integrity.

Being able to localize content in pharma forms a vital part of any successful commercial launch strategy.

• Global teams need tools that allow regional markets to easily localize content in pharma. This could include translating materials accurately and efficiently. Without the right technology, the customization process—including translation—can become lengthy, labor-intensive, and resource-intensive. An inefficient customization process delays content reaching the field.
• Tools like BaseCase support flexibility by enabling translation-ready modular content. Using it allows field teams to make quick, compliant adjustments for each language or region. This capability is essential for making materials accessible to diverse audiences without compromising consistency.

• When local teams are not involved early in the content creation process, important regional considerations can be overlooked. Global teams may aim to provide universally relevant materials. However, these materials often miss nuances that could have been integrated if they involved regional representatives from the beginning.
• Early engagement with local teams can help capture local data needs, regulatory constraints, and messaging preferences. This approach makes it easier to localize content in pharma from the outset. Additionally, involving local experts in reviewing translations ensures accuracy and relevance, especially for specialized medical or market access terminology.